Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the Gulf

NCT05266469 · clinicaltrials.gov ↗

COMPLETED

Status

168

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing Multiple Sclerosis

Interventions

OTHER: Ofatumumab
OTHER: Ocrelizumab

Sponsor

Novartis Pharmaceuticals